Consolidated Statements of Changes In Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Series 1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018		$ 3	$ 9,727	$ (4,952)	$ 4,778
Balance, shares at Dec. 31, 2018		2,558,419
Stock-based compensation - restricted stock			75		75
Stock-based compensation - restricted stock units			36		36
Stock-based compensation - stock options			313		313
Issuance of common stock in September capital raise			500		500
Issuance of common stock in September capital raise,shares		69,114
Net loss				(7,830)	(7,830)
Balance at Dec. 31, 2019		$ 3	10,651	(12,782)	(2,128)
Balance, shares at Dec. 31, 2019		2,627,533
Issuance of Common Stock in ArTara Private Placement, net of offering costs			1,867		1,867
Issuance of Common Stock in ArTara Private Placement, net of offering costs, shares		284,875
Issuance of Common Stock in Proteon Private Placement, net of offering costs		$ 2	12,411		12,413
Issuance of Common Stock in Proteon Private Placement, net of offering costs, shares		1,896,888
Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs			25,319		25,319
Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs, shares	3,879
Reverse business combination		$ 1	34,532		34,533
Reverse business combination, shares		1,033,907
Issuance of Common Stock in Common Offering, net of offering costs		$ 4	73,566		73,570
Issuance of Common Stock in Common Offering, net of offering costs, shares		4,600,000
Issuance of Series 1 Convertible Preferred Stock in Preferred Offering, net of offering costs			66,284		66,284
Issuance of Series 1 Convertible Preferred Stock in Preferred Offering, net of offering costs, shares	4,148
Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs		$ 1	11,086		11,087
Issuance of Common Stock in Common Offering (Underwriters Overallotment Option), net of offering costs, shares		690,000
Settlement of restricted stock units
Settlement of restricted stock units, shares		20,870
Exercise of stock options			530		530
Exercise of stock options, shares		57,767
Stock-based compensation - restricted stock
Stock-based compensation - restricted stock units			6,357		6,357
Stock-based compensation - stock options			3,389		3,389
Net loss				(33,978)	(33,978)
Balance at Dec. 31, 2020		$ 11	$ 245,992	$ (46,760)	$ 199,243
Balance, shares at Dec. 31, 2020	8,027	11,211,840